Amikacin Pharmacokinetics in Pediatric Patients with Burn Injuries Compared to Those with Oncology Conditions

Authors

Xiaoxi Liu
Anne Smits
Tian Yu
Stephanie Wead
Alice Neely
Richard J. Kagan
Daniel P. Healy
Karel Allegaert
Catherine M.T. Sherwin, Wright State UniversityFollow

Document Type

Conference Proceeding

Publication Date

2016

Abstract

Physiologic changes due to disease status can lead to highly variable pharmacokinetics (PK) of amikacin in children. Therefore, considerations should be given when determining optimal amikacin does for patients with a specific diseases. Improved understanding of factors influencing PD can allow for the optimizing of dosage regimens to reduce adverse effects.

The aim of the study was to undertake a comparative pharmacometic analysis of amikacin use in pediatric patients with burn injuries verses those with oncology conditions.

Comments

World Conference of Pharmacometrics (WCoP), Brisbane, Australia.

Repository Citation

Liu, X., Smits, A., Yu, T., Wead, S., Neely, A., Kagan, R. J., Healy, D. P., Allegaert, K., & Sherwin, C. M. (2016). Amikacin Pharmacokinetics in Pediatric Patients with Burn Injuries Compared to Those with Oncology Conditions. .
https://corescholar.libraries.wright.edu/pediatrics/321